Puma Biotechnology (PBYI) Gross Margin (2017 - 2026)
Puma Biotechnology's (PBYI) quarterly Gross Margin came in at 76.74% in Q1 2026, down 32.0% YoY from 112.85% in Q1 2025, and up 10.66% on a QoQ basis from 69.35% in Q4 2025.
Puma Biotechnology (PBYI) Gross Margin (2017 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 10 years of Gross Margin data on file, last reported at 76.74% in Q1 2026.
- Quarterly Gross Margin fell 32.0% year-over-year to 76.74% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 74.46% (up 206.0% YoY) and the FY2025 annual result came in at 74.53%, up 248.0% from the prior year.
- Gross Margin climbed to 76.74% in Q1 2026, from 69.35% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 80.79% in Q4 2022 to a low of 63.87% in Q3 2024.
- A 5-year average of 75.09% and a median of 76.44% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin slumped 1449 bps — and 2025, when it jumped 1378 bps.
- Tracing PBYI's Gross Margin over 5 years: stood at 80.79% in 2022, then dropped by 18 bps to 66.3% in 2023, then grew by 15 bps to 76.44% in 2024, then fell by 9 bps to 69.35% in 2025, then rose by 11 bps to 76.74% in 2026.
- The last three Gross Margin figures came in at 76.74% (Q1 2026), 69.35% (Q4 2025), and 77.65% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 77.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.92% |
| Mar 31, 2026 | 76.74% |
| Dec 31, 2025 | 69.35% |
| Sep 30, 2025 | 77.65% |
| Jun 30, 2025 | 76.54% |
| Mar 31, 2025 | 77.06% |
| Dec 31, 2024 | 76.44% |
| Sep 30, 2024 | 63.87% |
| Jun 30, 2024 | 77.36% |
| Mar 31, 2024 | 75.49% |
| Dec 31, 2023 | 66.30% |
| Sep 30, 2023 | 76.33% |
| Jun 30, 2023 | 78.27% |
| Mar 31, 2023 | 74.95% |
| Dec 31, 2022 | 80.79% |
| Sep 30, 2022 | 78.12% |
| Jun 30, 2022 | 74.94% |
| Mar 31, 2022 | 76.29% |
| Dec 31, 2021 | 78.51% |
| Sep 30, 2021 | 77.77% |